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Background: The presence of the Y-chromosome or Y chromosome-derived material is seen in 4-60% of Turner
syndrome patients (Chromosomal Disorders of Sex Development (DSD)). DSD patients with specific Y-chromosomal
material in their karyotype, the GonadoBlastoma on the Y-chromosome (GBY) region, have an increased risk of
developing type II germ cell tumors/cancer (GCC), most likely related to TSPY. The Sex determining Region on the
Y gene (SRY) is located on the short arm of the Y-chromosome and is the crucial switch that initiates testis
determination and subsequent male development. Mutations in this gene are responsible for sex reversal in
approximately 10-15% of 46,XY pure gonadal dysgenesis (46,XY DSD) cases. The majority of the mutations
described are located in the central HMG domain, which is involved in the binding and bending of the DNA and
harbors two nuclear localization signals. SRY mutations have also been found in a small number of patients with a
45,X/46,XY karyotype and might play a role in the maldevelopment of the gonads.
Methods: To thoroughly investigate the presence of possible SRY gene mutations in mosaic DSD patients, we
performed next generation (deep) sequencing on the genomic DNA of fourteen independent patients (twelve 45,
X/46,XY, one 45,X/46,XX/46,XY, and one 46,XX/46,XY).
Results and conclusions: The results demonstrate that aberrations in SRY are rare in mosaic DSD patients and
therefore do not play a significant role in the etiology of the disease.
Keywords: Disorders of Sex Development (DSD), Chromosomal-DSD, SRY, Next generation (deep) sequencing,
MutationBackground
The development of a mammalian embryo into either fe-
male or male is primarily dependent on the sex chromo-
somal constitution, being XX and XY respectively.
Normal male (46,XY) sex determination relies on the
presence of the Y-chromosome, specifically on expression
of SRY at the appropriate time and place during gonad de-
velopment. Timely expression of this gene above a critical
threshold is necessary to trigger testis formation [1,2]. If* Correspondence: l.looijenga@erasmusmc.nl
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reproduction in any medium, provided the orsufficient SRY is present, SOX9 will be up-regulated, lead-
ing to the formation of pre-Sertoli cells [3]. This will fur-
ther orchestrate the formation of a functional testis,
ultimately leading to the development of male primary
and secondary sex characteristics [2]. In a 46,XX constitu-
tion, (i.e. the absence of the Y-chromosome and SRY) sup-
portive cells in the gonad will, under the influence of
FOXL2, WNT4, and RSPO1 amongst others, develop as
granulosa and theca cells, leading to the formation of a
functional ovary and female primary and secondary sex
characteristics [2].
Turner syndrome (TS) is characterized by gonadal
dysgenesis, short stature, and dysmorphic features (neckal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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with a normal or abnormal Y-chromosome is identified
by standard cytogenetic techniques [4]. Patients with
chromosomal DSD as a result of a 45,X/46,XY karyotype
(mixed gonadal dysgenesis) may present with a wide
spectrum of phenotypes ranging from normal male
through ambiguous genitalia to female with a TS pheno-
type [5]. They are characterized by the presence of dys-
genetic testis and/or streak gonads, with persistence of
the Müllerian ducts and inadequate virilization, and
classically have a 45,X/46,XY karyotype. Y-chromosome
mosaicism may lead to virilization and modifications in
the female phenotype of TS patients, although a direct
correlation between presence of the Y-chromosome and
gonadal differentiation pattern has not been found [6,7].
The presence of a specific region of the Y-chromosome
in TS patients is correlated with an increased risk of
developing a GCC, namely the GonadoBlastoma on Y
region (GBY, i.e. TSPY) [8,9].
Mutations in the SRY gene are known to be involved
in 46,XY sex reversal and are found in approximately
15% of 46,XY gonadal dysgenesis cases [10]. Most of the
mutations detected are located in the HMG domain,
responsible for the binding and bending of DNA, but
several mutations outside of this domain have been
reported. Several reports have also described mutations
in the SRY gene in individuals with a 45,X/46,XY karyo-
type [11-14], suggesting an additional effect of mutant
SRY in the gonadal development of these patients.
Until recently the detection of genetic variants present
in <50% of cells was technically challenging, as conven-
tional Sanger sequencing does not routinely reveal such
changes. The development of next-generation sequen-
cing technology has greatly simplified this type of ana-
lysis, as the potential to generate millions of sequence
reads allows the detection and precise quantitation of
low frequency variants. This approach has been used for
identifying mosaic changes in a range of different sam-
ples types [15-17]. Here we describe the analysis of the
SRY gene using the 454 GS/FLX sequencer in fourteen
mosaic patients, including twelve patients with 45,X/46,
XY, one patient with a 45,X/46,XX/46,XY, and one
patient with a 46,XY/46,XX karyotype, to evaluate the
potential role of SRY mutations in these patients.
Results
In total fourteen chromosomal DSD patients with a
mosaic karyotype were included in the study: twelve
patients with a 45,X/46,XY, one patient with a 45,X/46,
XX/46,XY, and one patient with a 46,XY/46,XX sex
chromosomal DSD (Table 1). Age at biopsy or gonadec-
tomy ranged from 6 months to 17 years of age (median
age 3 years, Table 1). From seven patients the karyotype
in peripheral blood lymphocytes was determined (cases1–3, 5, 8, 12 and 14), and of five patients the gonadal
karyotype was known (case 1–4, and 12). Conventional
Sanger sequencing of SRY has been performed on
genomic DNA from two patients (case 1 and 8), reveal-
ing no aberrations. Eight patients (57%) had a male, and
six patients (43%) had a female gender. Histology of the
gonads showed streak gonads, undifferentiated gonadal
tissue, ovotesticular and testicular differentiation
patterns. In one case no gonadal tissue was found (case
7), only adnexal structures (fallopian tubes, epididymis
and an underdeveloped/dysplastic uterus). In one patient
(case 3) a gonadoblastoma was described, being the
precursor lesion of the type II germ Cell Tumor/Cancer
(GCC) in the dysgenetic gonad [9].
Two different PCR products from each of the 14
different samples were generated, such that each could
be identified by a specific 10 nt barcode sequence
Additional file 1: Table S1). As the first 9 nt of these
barcodes (plus the first 3 nt of the SRY-specific
sequences) were sufficient to differentiate each of the
products, we used the 10th nt of the barcode to estimate
the sensitivity of the assay. The advantage of using
barcode sequences for this is that they were incorpo-
rated during synthesis of the primers used for generating
the PCR products. This avoids any low level mosaicism
that could theoretically be present in any of the samples
being identified, giving misleading sensitivity estimates.
Although the 10th barcode nt was close to the 5’ end of
the read, and potentially expected to have a low error
rate, a previous study of 454 sequencing showed that
there was no correlation between error rate and distance
from the 5’ end for the first 100 bp of the read [17].
There were 56 different sets of reads, consisting of for-
ward and reverse reads from two PCR products derived
from 14 different samples. In total 194,680 reads con-
tained the first 9 bp of any of the different barcodes
used, of which only 143 (0.07%) contained a non-
matching 10th bp for the corresponding barcode
(Additional file 1: Table S1).
When pooling the PCR products prior to sequencing an
attempt was made to include equal amounts of each prod-
uct, and analysis showed that 49/56 sets of reads were
within 2x the number of reads of the corresponding mean.
The sample with the lowest representation was present at
only 0.9%, compared to the expected 1/14 or 7.1%. Despite
this low level, an incorrect 10th nt in this sample was
detected in only 0.4% (2/495) of reads. These error rates
are lower than previously reported figures of ~1%, pre-
sumably due to the fact that higher error rates have been
shown to correlate with specific sequence features e.g.
homopolymer stretches. To allow for this we set our lower
threshold for variant detection at 2%.
Using this threshold, a variant in >2% of reads was iden-
tified in only one case (Sample 14, Table 1). This was a
Table 1 Overview of sex, karyotype, SRY variants and gonadal histology in mosaic DSD patients
Case No Sex Karyotype
(%) [%]
SRY Variants Histology of the gonads UGT OT NGT Other NA Age biopsy/gonadectomy
T O S # Years
1 F 45X/46XY
(10%:90%)
[58%/42%]
+ (L + R) 17
2 M 45,X/46,X,der(Y)
(pter-q11.2::q11.2-pter)
(44%:56%) [T:71%/29%;
UGT: 63%/37%]
+ (R) + (L) 6 months
3 F 45X/46XY (56%:44%)
[Y present§]
+ (GB) (L) 17
4 M 45X/46X iso Y (NA)
[96%/4%]
+ (L) 6 months
5 F 45X/46XY
(50%:50%) [NA]
+ (R) 16
6 F 45X/46X iso Y
(NA) [NA]
+ (L + R) 1
7 M 45X/46XY (NA) [NA] + (R) 1
8 M 45X/46XY
(50%:50%) [NA]
+ (R) & 9 months
9 M 45X/46XY (NA) [NA] + NA
10 F 45X/46XY (NA) [NA] + (L + R) 15
11 M 45X/46XY (NA) [NA] + 3
12 F 46XX/46XY (94%:6%)
[T:16%/84%;
O: 68%/32%]
+ (NA) 1
13 M 45X/46XY (NA) [NA] + 5
14 M 45X/46XX/46XY
(39%:49%:12%) [NA]
c.49delT 21% + (L) 3
Reference Sex Karyotype (%) [%} SRY Variants T O S UGT OT NGT Other NA Years
[23] F 45X/46XXY
(65%/35%) [NA@]
p. Y3X + (L + R) ‡ NA
[11] F 45X/46XY
(82%/18%)
[L:94%/6%
R:98%/2% €]
p.S18N + (L + R) † 17
[11] F 45X/46X mar (Y)
(95.5%/0.5%)
[100%/0% €]
p.S18N + (L + R) † 14
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Table 1 Overview of sex, karyotype, SRY variants and gonadal histology in mosaic DSD patients (Continued)
[21] F 45X/46X psu dic
(Y)(pter-q11::q11-pter)
(40%/60%) [NA@]
p.R59G + (L + R) 24
[12] F 45X/46XY
(80%/20%) [NA]
p.N82X + (NA) * 24
[12] F 45X/46XY
(86%/14%) [NA]
p.L159TfsX167 + (NA) * 20
[12] F 45X/46XY
(89%/11%) [NA]
p.Q74H + (L + R) 22
[14] F 45X/46XY
(15%/85%) [NA]
rs11575897 + (GB) (L + R) $ 13.5
(%): Karyotype in blood, [%]: Gonadal karyotype, GB: Gonadoblastoma, NA: Not Available, T: Testis, O: Ovary, S: Streak, Tissue, OT: OvoTestis,
Ov St: Ovarian Stroma, UGT: Undifferentiated Gonadal, NGT: No Gonadal Tissue, L: Left side, R: Right side.
# Including ovarian stroma.
§ Not further specified.
@ Blood karyotype confirmed on gonadal tissue, not further specified.
& Contains germ cells positive for OCT3/4, TSPY, SCF: at risk for malignant transformation (pre-CIS).
‡ Gonads contained primordial follicles, not further specified.
† Macroscopically streak.
€ Karyotype assessed in fibroblasts cultured from gonads.
* Stromal tissue with similarities to testicular histopathology present, not further specified.
$ Described as Left dysgenetic testis with GB, Right dysgenetic gonad.
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http://www.biomedcentral.com/1471-2350/13/108deletion of T on nucleotide position 197 in the SRY gene
(c.49delT in reference sequence NM_003140.1) which was
identified in 21% of sequence reads of the 45,X/46,XX/46,
XY patient. Subsequent analysis of sample 14 by subclon-
ing PCR product and analyzing 30 samples by conven-
tional Sanger sequencing, could not confirm the deletion
originally found by deep sequencing (data not shown).
Discussion
SRY is the founding member of the SRY-like HMG box
(SOX) family of transcription factors, characterized by a
HMG domain [18]. It is involved in the binding and
bending of DNA and contains two nuclear localization
signals. Mutations in SRY are present in 10-15% of 46,
XY DSD patients [10], and these patients have an
increased risk of developing GCC, related to the pres-
ence of the GBY region (with TSPY as the most likely
candidate gene), and the prolonged expression of
OCT3/4 (POU5F1) in the germ cells [8,19,20]. Several
authors have described mutations in SRY in rare cases
with a mosaic sex chromosome constitution [11-13,21-
23], indicating a potential involvement of SRY in abnor-
mal gonadal development of 45,X/46,X,der(Y) patients.
However, in this study no confirmed mutations in SRY
were identified in any of the fourteen cases analyzed. In
case no. 14 with a 45,X/46,XX/46,XY karyotype, a
deletion of T on position 197 of SRY (ref. seq.
NM_003140.1) was found by deep sequencing in 21% of
the sequence reads. However, subsequent analysis by se-
quencing subcloned PCR products only produced wild
type SRY sequences, indicating that the original deep se-
quencing result was most likely a false positive. The
results presented here are in agreement with, and extend
the data reported by (and others summarized in) Nishi
et al. [14], who found only one SRY polymorphism
(c.561C→T) in a group of 27 patients (fourteen TS and
thirteen mixed gonadal dysgenesis patients. In Table 1,
next to the cases analyzed here, an overview of SRY
mutations that have been reported in chromosomal DSD
cases is shown. The results published until now, showing
a SRY mutation in approximately 8% of cases, have all
been obtained using conventional Sanger sequencing;
the findings presented here show that, although analyzed
with a highly sensitive sequencing technique, variations
in SRY are not common in patients with a mosaic sex
chromosomal constitution.
Shahid et al. [13] describes a mosaic TS patient,
with gonadoblastoma, having a frameshift mutation
(L94fsX180) in SRY which was inherited from the
father. He was found to be mosaic for the SRY muta-
tion and had oligoasthenozoospermia and a testicular
GCC (seminoma), which are signs of mild Testicular
Dysgenesis Syndrome (TDS), the underlying entity
proposed by Skakkebæk et. al. [24]. They suggest thatthe presence of the mutated SRY gene might play a role
in the development of gonadoblastoma and seminoma,
being the precursor lesion and the invasive component
of GCC respectively. However, in the series of samples
analyzed here and published by others, no clear link be-
tween presence of SRY mutations and development of a
gonadoblastoma in these patients can be made (Table 1
and references therein). Domenice et al. [22] describe a
patient with partial gonadal dysgenesis and a SRY mis-
sense (S18N) mutation whose unaffected male relatives
also harbored the mutation, showing no link between
SRY mutation and TDS. However, a family with two sis-
ters with 46,XY DSD, pure gonadal dysgenesis and a
phenotypically normal brother has been described, in
which a SRY frameshift mutation was found in the two
sisters and in a mosaic constitution in their father. He
showed signs associated with TDS; hypospadias, crypt-
orchidism, a testicular GCC (seminoma) and oli-
goasthenozoospermia, suggesting that mutations in
SRY may be associated with TDS [25]. If variations in
SRY play a significant role in TDS and the development
of a testicular GCC remains unresolved, and may war-
rant further investigation.
It has been found in chimeric XX-XY mouse models
that if the gonad contains less than 30% Y-positive cells,
the gonad will develop as an ovary, suggesting a correl-
ation between percentage of Y-containing cells and the
gonadal differentiation pattern [26]. This seemed at first
to be confirmed in humans [27,28], however two subse-
quent case reports and analysis of a larger series of sam-
ples show no correlation between the degree of gonadal
mosaicism and differentiation pattern [6,29,30]. The
study by Cools et al. [6] revealed no clear correlation
between peripheral blood karyotype and gonadal
karyotype, or between the gonadal karyotype and differ-
entiation pattern found in the gonads. The inconsistency
between gonadal karyotype and gonadal differentiation
pattern cannot be explained by the presence of SRY
mutations, as they are found only in rare cases, and do
not seem to correlate with the differentiation pattern
reported [11,12,14,21,23], even when ascertained by a
highly sensitive next generation sequencing approach, as
shown in this study.
Conclusion
This is, to our knowledge, the first study using next gen-
eration sequencing to detect mutations in the SRY gene
in chromosomal DSD patients with a mosaic karyotype.
Although a highly sensitive method [15-17], no aberra-
tions in SRY were detected. Including the present study,
a total of 91 patients with a mosaic sex chromosomal
constitution have been screened for SRY mutations, of
which only seven (8%) showed a variation. This indicates
that mutations in SRY are rare in chromosomal DSD
Hersmus et al. BMC Medical Genetics 2012, 13:108 Page 6 of 7
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a minority of cases.
Methods
Tissue and DNA samples
Anonymized tissue samples were collected from our
diagnostic archives and diagnosed according to WHO
standards [31] by an experienced pathologist (JWO).
Use of tissue samples for scientific reasons was approved
by the Medical Ethical Committee ErasmusMC (MEC
02.981 and CCR2041). Samples were used according to
the “Code for Proper Secondary Use of Human Tissue
in The Netherlands” as developed by the Dutch Feder-
ation of Medical Scientific Societies (FMWV (Version
2002, update 2011). Genomic DNA for sequencing was
isolated from peripheral blood lymphocytes following
standard protocols.
Primer design and PCR amplification
SRY specific priming sequences were designed using refer-
ence sequence NG_011751. The complete coding se-
quence was covered in two overlapping PCR products,
generating products of 383 bp and 372 bp. To facilitate
analysis on the 454 GS/FLX sequencer (454 Life Sciences,
Branford, CT, USA) the SRY-specific sequences were
modified by adding a) the forward or reverse Titanium
Primer and b) a 10 nucleotide multiplex identifier se-
quence, allowing all samples to be combined into a single
reaction. All sequences are outlined in Additional file 1:
Table S1. PCR amplification was carried out in 25 μl
volumes, using 1.25 U Pfusion High Fidelity Enzyme per
reaction. Cycle conditions were: 1 cycle of 94°C for 1 min;
35 cycles of 94°C for 30 sec, 62°C for 30 sec, 72°C for 1
min; 1 cycle of 72°C for 10 min. Samples were analyzed on
a 1% agarose gel, then purified using the Agencourt
AMPure XP kit (Beckman Coulter Genomics, Danvers,
MA, USA) following the manufacturer’s protocol.
Sequencing and data analysis
PCR products were pooled in equimolar concentrations
and sequenced on the 454 GS/FLX sequencer (454 Life
Sciences) at the Australian Genome Research Facility
(Melbourne, Australia) following manufacturer’s instruc-
tions. The reads were de-multi-plexed based on the
unique 10 nt MID sequence. Variant detection was per-
formed with NextGene (SoftGenetics, State College PA,
USA), using NG_011751 as the reference sequence for
alignment. Only variants present in >2% of reads for a
given sample were chosen for further analysis.
PCR amplification and sequencing of sample 14
DNA was amplified using SRY specific primers SRY-up
5’-TTCAATTTTGTCGCAACTCTCC-3’ and SRY-rev
5’-GATCGAATGCGTTCATGGGTC-3’, generating aproduct of 237 bp. PCR amplification was performed
using the BD Advantage 2 kit (BD Biosciences, Palo
Alto, CA, USA). Cycle conditions were: 1 cycle of 95°C
for 1 min; 45 cycles of 95°C for 45 sec, 57°C for 45 sec,
68°C for 1 min; 1 cycle of 68°C for 3 min. PCR product
was analyzed on 1% agarose gel. Subsequently PCR
product was cloned, transformed, plated and positive
clones were analyzed using the TOPO TA Cloning Kit
For Sequencing, following manufacturers instructions
(Invitrogen, Life Technologies, Carlsbad, CA, USA).
Sequences reactions were done with standard T3 and T7
primers, using the ABI PRISM BigDye Terminator Cycle
Sequencing Ready Reaction kit and run on an ABI
3130xl Genetic Analyzer (Applied Biosystems, Life Tech-
ologies, Carlsbad, CA, USA) following manufacturer’s
instructions. Sequences were analyzed with Mutation-
Surveyor software (Softgenetics, State College, PA, USA)
using reference sequence NG_011751.
Additional file
Additional file 1: Table S1. Primers used for analyzing the 14 samples.
Listed are the 56 different sequences that were used for amplifying two
PCR products covering the SRY gene. Each primer consists of a 454-
specific sequence, a 10 nt barcode unique for each sample (in bold), and
a sequence for amplifying the SRY gene (italicised). The column “total
reads” shows how many reads contained the first 9 nt of the
corresponding barcode (plus the first 3 nt of the SRY primer to
differentiate the two different PCR products), irrespective of the 10th nt
of the barcode sequence. The column “total correct reads” shows how
many reads contained the expected 10th nt of the corresponding
barcode.
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